Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Access to novel hepatitis C virus (HCV) antiviral therapies is restricted.
• Existing treatments necessitate optimized strategies for genotype 1 patients.

Purpose of the Study:

• To develop a response-guided management roadmap for HCV genotype 1 using existing antiviral therapies.
• To optimize treatment duration and drug exposure based on early viral load monitoring.

Main Methods:

• A systematic literature search identified randomized controlled trials and meta-analyses on response-guided therapy for HCV genotype 1.
• Pegylated interferon and ribavirin (PR), boceprevir (B), and telaprevir (T) regimens were analyzed.
• A management roadmap was created based on sustained virological response (SVR) at specific time points (TW4, TW8, TW10, TW12).

Main Results:

• Patients with undetectable HCV RNA at week 4 (TW4) achieved >86% SVR with PR, or could receive 24 weeks of PR or 28 weeks of BPR.
• For patients positive for HCV RNA at TW4, 72 weeks of PR yielded 53% SVR, indicating BPR as a superior option.
• The
• 80-80
• rule emerged, where undetectable HCV RNA at TW4 or TW8 predicted >80% SVR, enabling shorter treatment durations.

Conclusions:

• A response-guided roadmap, particularly the
• 80-80
• rule, effectively guides HCV treatment decisions.
• This strategy achieves high SVR rates and minimizes unnecessary drug exposure in non-responders.
• The roadmap is applicable across treatment-naïve, treatment-failure, and cirrhotic patient populations.